GlassScriptPhysician profile
Naiga Dohnji
NPI 1912337205
$1,877.83
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.27 · 2022: $13.13 · 2023: $632 · 2024: $1,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,842.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $507.75 | 2022-2024 | |
| Supernus Pharmaceuticals, INC. | $466.79 | 2023-2024 | Qelbree, Qelbree |
| Lundbeck LLC | $184.06 | 2023-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $155.94 | 2023-2024 | Caplyta |
| Corium, LLC | $152.16 | 2023-2024 | Azstarys |
| Janssen Pharmaceuticals, INC | $147.10 | 2023-2024 | Spravato, Invega Trinza |
| Idorsia Pharmaceuticals US INC | $93.60 | 2023-2024 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $41.21 | 2021-2023 | Rexulti |
| Neurocrine Biosciences, INC. | $35.41 | 2023 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $34.86 | 2024 | Austedo Xr |
| Tris Pharma INC | $28.29 | 2023-2024 | Dyanavel Xr |
| Almatica Pharma LLC | $16.19 | 2023 | Loreev Xr |
| Owp Pharmaceuticals, INC. | $14.47 | 2023 | Lamotrigine, Subvenite |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naiga Dohnji listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.